BioDFence G3
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Prostatectomy, Erectile Dysfunction Following Radical Prostatectomy, Incontinence, Urinary
Trial Timeline
Apr 1, 2023 → Jun 30, 2024
NCT ID
NCT05363644About BioDFence G3
BioDFence G3 is a phase 3 stage product being developed by Integra LifeSciences for Prostate Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05363644. Target conditions include Prostate Cancer, Prostatectomy, Erectile Dysfunction Following Radical Prostatectomy.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05363644 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Prostate Cancer